NCT00995423已完成4 期
Comparison of the Efficacy and Safety of Paclitaxel-Eluting CoroflexTM Please Stent Versus Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease
CardioVascular Research Foundation, Korea10 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2008年4月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 500
- 试验地点
- 10
- 主要终点
- In-segment late lumen loss by quantitative coronary angiographic measurements
研究概览
简要总结
The purpose of this study is to assess whether the outcome of treatment with CoroflexTM Please stent is not inferior to the outcome of treatment with TAXUS stent.
详细描述
To establish the effectiveness and the safety of coronary stenting with the newly developed paclitaxel-eluting balloon expandable stent (CoroflexTM Please stent, B. Bran, Melsungen, Germany), compared to the conventional paclitaxel-eluting balloon expandable stent (TAXUS stent, Boston scientific) in the treatment of coronary stenosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient must be at least 18 years of age
- •Significant de novo coronary artery stenosis (>50% by visual estimation)
- •Patients with stable (CCS class 1 to 4) or acute coronary syndromes (unstable angina pectoris Braunwald class IB, IC, IIB, IIC, IIIB, IIIC or NSTEMI) or patents with atypical chest pain or without symptoms but having documented myocardial ischemia, amenable to stent-assisted percutaneous coronary intervention
- •The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site
排除标准
- •The patient has a known hypersensitivity or contraindication to any of the following medications:
- •Both Clopidogrel and TIclopidine
- •Sirolimus, paclitaxel
- •Stainless steel and/or
- •Contrast media (patients with documented sensitivity to contrast which can be effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled)
- •Systemic (intravenous) Sirolimus or paclitaxel use within 12 months
- •Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
- •History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions
- •Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months
- •Current known current platelet count <100,000 cells/mm3 or Hgb <10 g/dL
- •An elective surgical procedure is planned that would necessitate interruption of thienopyridines during the first 12 months post enrollment
- •Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
- •Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period
- •Patients with EF<25%
- •Cardiogenic shock at entry
- •Acute MI patients within symptom onset < 12 hours needing primary angioplasty
- •Creatinine level > 3.0mg/dL or dependence on dialysis
- •Patients with left main stem stenosis (>50% by visual estimate)
结局指标
主要结局
In-segment late lumen loss by quantitative coronary angiographic measurements
时间窗: 9 months
次要结局
- All Death(12 months)
- Cardiac death(12 months)
- Myocardial infarction(12 month)
- Target vessel revascularization (all and ischemia-driven)(12 month)
- Target lesion revascularization (all and ischemia-driven)(12 months)
- Stent thrombosis (by ARC definition)(12 months)
- In-stent late loss at 9 month angiographic follow-up(12 months)
- Binary restenosis in both in-stent and in-segment(9 month)
- Angiographic pattern of restenosis(9 months)
- Procedural success defined as achievement of a final diameter stenosis of <30% by QCA using any percutaneous method, without the occurrence of death, Q wave MI, or repeat revascularization of the target lesion(during the hospital stay)
研究者
研究点 (10)
Loading locations...
相似试验
撤回
2 期
Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple MyelomaRelapse/Refractory Multiple MyelomaNCT02985333Sun Yat-sen University
进行中（未招募）
不适用
Safety and Efficacy of Paclitax Coated Balloon in Patients With Coronary In-stent Restenosis (ISR)In-stent RestenosisNCT05656118Yonsei University260
Unknown
2 期
Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric CancerAdvanced Gastric CancerNCT02072317Fudan University140
Unknown
不适用
A Study of Below The Knee Arteries' Stenosis or Occlusion Treated With LEGFLOW OTWPeripheral Artery DiseaseNCT02962232ZhuHai Cardionovum Medical Device Co., Ltd.172
已完成
1 期
DEBlue Stent vs Cypher Stent in the Treatment of Advanced Coronary Artery DiseaseCoronary Artery DiseaseNCT00473772University Hospital, Saarland643